← Back to Screener
United Therapeutics Corp (UTHR)
Price$580.51
Favorite Metrics
Price vs S&P 500 (26W)24.67%
Price vs S&P 500 (4W)3.08%
Market Capitalization$25.27B
P/E Ratio (Annual)18.93x
All Metrics
P/CF (Annual)16.19x
Book Value / Share (Quarterly)$162.60
P/TBV (Annual)2.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.02%
Cash Flow / Share (Quarterly)$23.72
Price vs S&P 500 (YTD)15.90%
Gross Margin (TTM)87.92%
Net Profit Margin (TTM)41.94%
EPS (TTM)$27.90
10-Day Avg Trading Volume0.57M
EPS Excl Extra (TTM)$27.90
Revenue Growth (5Y)16.50%
EPS (Annual)$27.86
ROI (Annual)18.81%
Gross Margin (Annual)87.92%
Net Profit Margin (5Y Avg)38.31%
Cash / Share (Quarterly)$66.91
P/E Basic Excl Extra (TTM)18.93x
Revenue Growth QoQ (YoY)7.38%
EPS Growth (5Y)19.27%
P/E Normalized (Annual)18.93x
ROA (Last FY)16.94%
Revenue Growth TTM (YoY)10.61%
EBITD / Share (TTM)$34.25
ROE (5Y Avg)16.20%
Operating Margin (TTM)46.89%
Cash Flow / Share (Annual)$23.72
P/B Ratio3.56x
P/B Ratio (Quarterly)2.96x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)7.45x
Net Interest Coverage (TTM)42.15x
ROA (TTM)17.29%
EPS Growth QoQ (YoY)23.98%
EV / EBITDA (TTM)14.46x
EPS Incl Extra (Annual)$27.86
Current Ratio (Annual)6.60x
Quick Ratio (Quarterly)6.28x
3-Month Avg Trading Volume0.49M
52-Week Price Return103.15%
EV / Free Cash Flow (Annual)22.91x
P/E Incl Extra (TTM)18.93x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$159.93
P/S Ratio (Annual)7.94x
Asset Turnover (Annual)0.40x
52-Week High$607.89
Operating Margin (5Y Avg)45.80%
EPS Excl Extra (Annual)$27.86
CapEx CAGR (5Y)54.73%
Tangible BV CAGR (5Y)16.52%
26-Week Price Return28.66%
Quick Ratio (Annual)6.28x
13-Week Price Return19.73%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.60x
Enterprise Value$23,714.164
Revenue / Share Growth (5Y)14.85%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)16.34%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)2.25x
Pretax Margin (Annual)53.85%
Cash / Share (Annual)$66.91
3-Month Return Std Dev47.63%
Gross Margin (5Y Avg)90.20%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)17.35%
EBITDA Interim CAGR (5Y)18.91%
ROE (Last FY)18.81%
Net Interest Coverage (Annual)8.76x
EPS Basic Excl Extra (Annual)$27.86
P/FCF (TTM)24.41x
Receivables Turnover (TTM)10.11x
EV / Free Cash Flow (TTM)22.91x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$27.90
Receivables Turnover (Annual)10.11x
ROI (TTM)19.16%
P/S Ratio (TTM)7.94x
Pretax Margin (5Y Avg)49.28%
Revenue / Share (Annual)$66.44
Tangible BV / Share (Annual)$160.67
Forward P/E19.68x
Free OCF CAGR (5Y)8.25%
Price vs S&P 500 (52W)73.32%
P/E Ratio (TTM)18.93x
EPS Growth TTM (YoY)13.31%
Year-to-Date Return18.54%
5-Day Price Return0.49%
EPS Normalized (Annual)$27.86
ROA (5Y Avg)13.63%
Net Profit Margin (Annual)41.94%
Month-to-Date Return-2.60%
Cash Flow / Share (TTM)$19.22
EBITD / Share (Annual)$34.24
EPS Growth (3Y)22.94%
Operating Margin (Annual)46.89%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)16.19x
ROI (5Y Avg)14.85%
P/E Excl Extra (TTM)18.93x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$27.90
P/TBV (Quarterly)3.01x
P/B Ratio (Annual)2.96x
Inventory Turnover (TTM)2.25x
Pretax Margin (TTM)53.85%
Book Value / Share (Annual)$162.60
Price vs S&P 500 (13W)19.05%
Net Margin Growth (5Y)3.86%
Beta0.64x
P/FCF (Annual)24.41x
Revenue / Share (TTM)$67.29
ROE (TTM)19.30%
52-Week Low$272.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.05
4.05
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
UTHRUnited Therapeutics Corp | 7.94x | 10.61% | 87.92% | 19.27% | $580.51 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
United Therapeutics Corp develops and markets therapies for pulmonary arterial hypertension (PAH), a rare and progressive lung disease characterized by elevated blood pressure in the pulmonary arteries. The company's portfolio centers on treprostinil-based treatments, with Tyvaso DPI (inhalation powder) as its primary revenue driver, supported by Remodulin (injection), Orenitram (extended-release tablets), Adcirca (tadalafil), and Unituxin. The U.S. market generates the majority of revenue, though the company maintains a presence in international markets.